Company profile: Reneo Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of therapies in development for rare genetic mitochondrial and orphan metabolic diseases. Develops mavodelpar (REN001) for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD), with a global Phase 2b trial in PMM and completed exploratory Phase 1b trials in LC-FAOD and McArdle disease.
Products and services
- Mavodelpar (REN001): Investigational therapy engineered to improve primary mitochondrial myopathies and long-chain fatty acid oxidation disorders, in Phase 2b for PMM with completed exploratory Phase 1b in LC-FAOD and McArdle disease
- Global Phase 2b PMM Trial: Global program conducts an ongoing Phase 2b clinical study in primary mitochondrial myopathy patients to evaluate mavodelpar, progressing therapy development for rare genetic mitochondrial diseases
- Exploratory Phase 1b LC-FAOD and McArdle Trials: Exploratory program completed Phase 1b clinical studies of mavodelpar in long-chain fatty acid oxidation disorders and McArdle disease, advancing investigation in rare mitochondrial indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Reneo Pharmaceuticals
Third Harmonic Bio
HQ: United States
Website
- Description: Provider of a clinical-stage, first-in-class, highly selective oral small molecule KIT inhibitor for mast cell-mediated inflammatory diseases; THB335 is being developed for chronic spontaneous urticaria, severe asthma, and other related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Third Harmonic Bio company profile →
Gesynta Pharma
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing mPGES-1–inhibiting drug candidates to reduce inflammation and pain. Pipeline includes vipoglanstat (GS-248), a non-hormonal treatment for endometriosis in phase II, and GS-073 for chronic inflammatory pain entering phase I. Research originates from Karolinska Institutet; GS-073 from AstraZeneca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gesynta Pharma company profile →
Graviton
HQ: United States
Website
- Description: Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
Aditxt
HQ: United States
Website
- Description: Provider of biotechnology solutions using novel nucleic acid-based technologies, including AditxtScore for personalized immune profiling; Apoptotic DNA Immunotherapy (ADI) to induce immune tolerance for transplants, autoimmune diseases, and allergies; Adimune for restoring immune tolerance; Pearsanta for personalized diagnostic and monitoring services; and Adivir developing medicines, diagnostics, and vaccines for public health threats.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aditxt company profile →
Acelyrin
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, identifying, acquiring, and accelerating development and commercialization of candidates including Izokibep (IL-17A inhibitor for psoriatic arthritis and hidradenitis suppurativa), Lonigutamab (subcutaneous anti-IGF-1R for thyroid eye disease), and SLRN-517 (fully human monoclonal targeting c-KIT for chronic urticaria and other mast cell-driven diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acelyrin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Reneo Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Reneo Pharmaceuticals
2.2 - Growth funds investing in similar companies to Reneo Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Reneo Pharmaceuticals
4.2 - Public trading comparable groups for Reneo Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →